Ibrance Impresses in New Breast Cancer Study

Share this content:
Ibrance Impresses in New Breast Cancer Study
Ibrance Impresses in New Breast Cancer Study
(Reuters) -- Pfizer said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance (palbociclib), was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients. The successful trial ...
READ FULL ARTICLE From Medical Page Today
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »